Navigation Links
Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
Date:10/24/2007

administered together at the recommended doses. The MTD was reached and the Companies have initiated the Phase II portion of the study with a recommended dose of 90mg of MGCD0103 in patients with pancreatic cancer. In addition, the pharmacokinetic profile of MGCD0103 appeared not to be altered when administered in combination with Gemzar.

Of the 21 patients enrolled in the study, 13 were evaluable for efficacy at the time of analysis. In summary, of the 13 evaluable patients there was one partial response (PR - RECIST criteria, unidimensional greater than or equal to 30% shrinkage) and eight stable disease (SD). In addition, five of the 13 evaluable patients experienced tumor shrinkage. The PR and a near PR (SD with 29% tumor shrinkage) were observed in pancreatic cancer patients, both of whom remain on study having received six and three cycles of treatment, respectively. Importantly, of the four evaluable patients with pancreatic cancer, there was one PR and three SD, which includes the one near PR.

"MGCD0103 is a very interesting compound as it is the first rationally-designed isotype-selective HDAC inhibitor in clinical development," said Dr. Herbert Hurwitz. "The current study is meant to follow up on strong preclinical data in pancreatic cancer, including synergy with gemcitabine. The Phase I stage of this study shows that the combination of MGCD0103 with gemcitabine is safe with preliminary signs of efficacy in pancreatic cancer. The Phase II stage of the study has been initiated and will better define the potential role of MGCD0103 in patients with pancreatic cancer."

"We are pleased to observe the preliminary tolerability and early signs of clinical activity for the MGCD0103 and Gemzar combination in solid tumor patients and particularly in pancreatic cancer patients. We look forward to expanding our enrollment in this underserved patient population and moving this trial forward during 2008," said Donald F. Corcoran, President and Chief Ex
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mass. , May 23, 2013  Haemonetics Corporation (NYSE: ... Lindop , CFO & EVP-Business Development, will present at ... Conference in Boston, MA on May ... http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may access ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... May 23, 2013  TeamHealth Medical Call Center ... and nurse advice lines, announces its newly formed ... nursing and administrative leaders, provides clinical expertise to ... cost-effective services for hospital clients, physician clients and ... system evolves, it,s imperative to continuously advance our ...
(Date:5/23/2013)... Mich. , May 23, 2013  Every day, their ... of air to his lungs. April and Bryan ... dire predictions weren,t true. "Quite a few doctors ... hospital alive," says April Gionfriddo , about ... desperate. Anything that would work, we would take it and ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... Cornerstone Pharmaceuticals, Inc., a leader in cancer ... preclinical toxicity study of azide drug-loaded Emulsiphan nano ... under a Collaboration Agreement. Emulsiphan is Cornerstone,s proprietary ... so pleased that Cornerstone has received a report ...
... Mangrove Partners, owners of 149,373 shares representing approximately 5.71% ... CPEX ), today announced that it has ... to CPEX,s Board of Directors to be implemented through ... to shareholders at $34.73 per share, composed of a ...
Cached Medicine Technology:Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study 2Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study 3Mangrove Partners Proposes Fully-Financed Dividend Recapitalization to Board of CPEX Pharmaceuticals, Inc. 2
(Date:5/25/2013)... (PRWEB) May 25, 2013 Dr. Farooq ... surgery clinic in Dubai, has announced his practice’s adoption ... is the only FDA-cleared femtosecond laser proven with more ... safety and precision of LASIK. , “We are happy ... Advanced Femtosecond Laser at our Dubai LASIK practice,” Ashraf ...
(Date:5/25/2013)... 25, 2013 Prairie Living at ... hosting an American Red Cross Blood Drive from 1:30 ... community, which is located at 955 Villa Ct. in ... those on Medicaid, who need some help to maintain ... Life," says Andrea Arview Frey, Director of Marketing for ...
(Date:5/25/2013)... 25, 2013 The current residents of Back2Basics ... and the B2B staff all came together Saturday, May 18th ... array of Indian Cuisine, the residents got up to thank ... them on their road to recovery, and giving them a ... Alcohol center in 2010 after realizing the need for a ...
(Date:5/24/2013)... Petersburg, FL (PRWEB) May 25, 2013 ... Cellulite Whisperer ® products from Sublime Beauty®. ... work to diminish cellulite, and many of the ingredients ... to deal with and is dreaded by many women," ... a concentrated holistic plan, women can diminish their cellulite." ...
(Date:5/24/2013)... ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale Now ... price reductions on their popular PhenObestin 37.5 non-prescription diet ... to lose weight as effortlessly as possible has reduced ... than 50%. , Bottles have been reduced from $149 ... orders will receive free shipping. , Made from ...
Breaking Medicine News(10 mins):Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2Health News:"Get Ready for Summer Sale" at Sublime Beauty® Continues: New Cellulite Whisperer® Products 2Health News:ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale Now On 2
... Incorporated,s (Nasdaq: VPHM ) third quarter financial results for ... 2009 before the open of the U.S. financial markets. , ... webcast at 9:00 a.m. Eastern Time on the same day. ... 2009 third quarter and other business. , The press ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today ... September 30, 2009 after the market closes on Wednesday, October ... Alan D. Gold, Chairman and Chief Executive Officer, and Kent ... conference call at 10:00 a.m. Pacific Time on Thursday, October ...
... Pa., Oct. 15 Pennsylvania,s commitment to children was recognized ... and mental health systems of care to the Department of ... the positive work we are doing on behalf of children ... programs and services supported by these grants, we are able ...
... , Prototype Anonymous Donor Database In Development , FAIRFAX, ... leading donor sperm providers have formed a new, non-profit ... AGDP will help donor gamete providers to share ... and activities to benefit individuals and organizations involved in ...
... Ohio, Oct. 15 The Longaberger Company is teaming up ... the fight against breast cancer. As part of the "Crucial ... clubs and players - in partnership with the American Cancer ... NFL games feature players, coaches and referees wearing pink game ...
... that the human papillomavirus vaccine might promote promiscuity, a ... the majority of respondents did not believe the HPV ... The study, conducted by University of Illinois at Chicago ... the November issue of the Journal of Adolescent ...
Cached Medicine News:Health News:ViroPharma to Release 2009 Third Quarter Financial Results on October 28, 2009 2Health News:BioMed Realty Trust to Report 2009 Third Quarter Results 2Health News:Department of Public Welfare Earns Federal Recognition for Programs and Services for Children 2Health News:UIC study finds girls aware of HPV vaccine's benefits 2
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: